UniProtKB/Swiss-Prot O43318: Variant p.Gly168Arg

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 168 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Glycine (G) to Arginine (R) at position 168 (G168R, p.Gly168Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In FMD2; increases autophosphorylation; no effect on MAPK signaling; no effect on NF-kappa-B signaling. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs886039233 [ dbSNP | Ensembl ]

Sequence information

Variant position: 168 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 606 The length of the canonical sequence.
Location on the sequence: QPKALIHRDLKPPNLLLVAG G TVLKICDFGTACDIQTHMTN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 606	Mitogen-activated protein kinase kinase kinase 7
Domain	36 – 291	Protein kinase
Region	1 – 300	Interaction with MAPK8IP1
Active site	156 – 156	Proton acceptor
Modified residue	184 – 184	(Microbial infection) O-acetylthreonine; by Yersinia YopJ; alternate
Modified residue	184 – 184	Phosphothreonine; by autocatalysis; alternate
Modified residue	187 – 187	(Microbial infection) O-acetylthreonine; by Yersinia YopJ; alternate
Modified residue	187 – 187	Phosphothreonine; by autocatalysis; alternate
Cross	158 – 158	Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis	158 – 158	K -> R. Abolishes ubiquitination.
Turn	166 – 169

Literature citations

Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia.
Wade E.M.; Daniel P.B.; Jenkins Z.A.; McInerney-Leo A.; Leo P.; Morgan T.; Addor M.C.; Ades L.C.; Bertola D.; Bohring A.; Carter E.; Cho T.J.; Duba H.C.; Fletcher E.; Kim C.A.; Krakow D.; Morava E.; Neuhann T.; Superti-Furga A.; Veenstra-Knol I.; Wieczorek D.; Wilson L.C.; Hennekam R.C.; Sutherland-Smith A.J.; Strom T.M.; Wilkie A.O.; Brown M.A.; Duncan E.L.; Markie D.M.; Robertson S.P.;
Am. J. Hum. Genet. 99:392-406(2016)
Cited for: INVOLVEMENT IN FMD2; VARIANTS FMD2 GLN-70; GLU-100; ARG-168 AND LEU-512; CHARACTERIZATION OF VARIANTS FMD2 LEU-512 AND ARG-168; SUBUNIT; MUTAGENESIS OF PRO-512;